About this trial
Stereotactic Ablative Radiotherapy, or SABR, is a modern radiotherapy technique that uses higher doses of radiation and 3D imaging techniques (CT, MRI, PET) to precisely target small tumors while aiming to spare healthy surrounding tissues and organs. Patients may receive their radiation treatment in multiple doses (MF, multi-fraction SABR), which – depending on the cancer type – may take weeks or months, yet may reduce later toxicity (side effects). Alternatively, treatment can be delivered in a single dose (SF, single-fraction SABR), which is more cost-effective and saves patient time. Both approaches are used in clinical care. This clinical trial compares these strategies, focusing on their impact on toxicity, progression-free survival, lesion size after therapy, quality of life, and cost-effectiveness.
Patient Profile
Patients diagnosed with one controlled primary tumour and 1-5 oligometastatic or oligoprogressive lesions.
Where’s this trial being run?
Beacon Hospital, Cork University Hospital, Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre, St Luke’s Hospital, University Hospital Galway, UPMC Whitfield Hospital Waterford, and Mater Private Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | SIMPLIFY-SABR-COMET |
|---|---|
| Number: | 24-09 |
| Full Title: | Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression |
| Principal Investigator: | Prof Aisling Barry (CUH) |
|---|---|
| Type: | Collaborative |
| Sponsor: | BC Cancer |
| Recruitment Started: |
Global: April 2025 Ireland: August 2025 |
| Global Recruitment Target: | 598 |
|---|---|
| Ireland Recruitment Target: | 70 |